Become an investor

BCAL Diagnostics (ASX: BDX) is commercialising a next-generation, patient-friendly diagnostic technology to assist in more effective diagnosis of breast cancer.
This page is intended to provide details about research and development for potential investors, commercial and distribution partners.

Investing in Science to
Brighten the Future

BCAL Diagnostics is developing blood screening technology that is intended to be used alongside breast cancer screening methods.
BCAL Diagnostics is developing diagnostic technology to assist in the early detection of breast cancer by identifying, measuring and validating specific biomarkers enriched in the patient’s blood.
Investing in BCAL Diagnostics provides an opportunity to support advancements in breast cancer diagnostics. Our focus on a non-invasive diagnostic technology that assists clinicians in early and accurate detection makes us a noteworthy investment. With alliances like the one with Precion Inc., we navigate regulatory processes diligently. By utilising technologies like Liquid Chromatography Mass Spectrometry, we maintain industry standards. Investing in BCAL aligns you with a company contributing to the evolution of breast cancer screening, presenting potential for societal impact and financial returns.

ASX Announcements

Read our latest shareholder announcements
NameDateSource
Change of Director's Interest Notice17/06/2024Download
Letter to Shareholders re General Meeting 15 July 202413/06/2024Download
Notice of General Meeting/Proxy Form13/06/2024Download
Cleansing Notice11/06/2024Download
Application for quotation of securities - BDX11/06/2024Download
Reinstatement to quotation03/06/2024Download
Proposed issues of securities03/06/2024Download
BCAL receive firm commitment to raise03/06/2024Download
Suspension from quotation31/05/2024Download
Response to price query30/05/2024Download
Trading Halt29/05/2024Download
Pause in Trading29/05/2024Download
Company presentation - investor insights02/05/2024Download
Change in substantial holding01/05/2024Download
4C Quarterly Activities26/04/2024Download
Initial Directors Notice03/04/2024Download
Ceasing to be a substantial shareholder03/04/2024Download
Trademark announcement02/04/2024Download
Change in substantial holding27/03/2024Download
Corporate Presentation06/03/2024Download
Appointment of Strategic CEO to Lead Commercial Launch06/03/2024Download
Final Directors Notice04/03/2024Download
Initial Directors Notice04/03/2024Download
BCAL to host Investor webcast01/03/2024Download
Cleansing notice28/02/2024Download
BCAL Strengthens Board with Appointment of Commercial NED29/02/2024Download
Quarterly Activities/Appendix 4C Cash Flow Report30/01/2024Download
Collaboration with KIMS & Indo-American Hospitals Hyderabad29/11/2023Download
BCAL Files Further Foundational Patent Application06/11/2023Download
Quarterly Activities/Appendix 4C Cash Flow Report31/10/2023Download
BCAL Locks Down Crucial Breast Cancer Signature11/09/2023Download
Shane Ryan Appointed Chief Operating Officer04/09/2023Download
Cleansing Notice01/09/2023Download
Application for quotation of securities - BDX01/09/2023Download
Preliminary Final Report30/08/2023Download
Share Purchase Plan Offer Booklet30/08/2023Download
Proposed issue of securities - BDX29/08/2023Download
$2.4m Capital Raise to Further BREASTEST Commercialisation28/08/2023Download
Investor Presentation24/08/2023Download
ASX Announcement - Trading Halt04/08/2023Download
BCAL Investor Education Update & Webinar08/08/2023Download
Breakthrough Results a Major Step Towards Commercialisation02/08/2023Download
ASX Annoucement28/07/2023Download
ASX Annoucement28/07/2023Download
Quarterly Activities/Appendix 4C Cash Flow Report27/07/2023Download
Shareholder Newsletter20/07/2023Download
ASX Annoucement30/06/2023Download
ASX Annoucements30/06/2023Download
BCAL appoints David Darling as an advisor16/05/2023Download
ASX Annoucement11/05/2023Download
ASX Annoucement03/05/2023Download
BCAL Opens Development & Clinical Service Laboratory03/05/2023Download
ASX Annoucement24/04/2023Download
ASX Annoucement16/01/2023Download
Recent Analysis Significantly Improves Commercial Prospects07/02/2022Download
Establishment of Development & Clinical Services Laboratory05/10/2022Download
BCAL Enters US Product Development Agreement with Precion28/06/2022Download
Shareholder Newsletter15/11/2022Download
Dr John Hurrell Appointed Chief Executive Officer11/01/2022Download
Notice of Annual General Meeting and Explanatory Statement21/10/2021Download
Australian Clinical Studies Launched03/09/2021Download
Market Update17/08/2021Download
Becoming a substantial holder22/07/2021Download
BCAL Diagnostics to list after raising $10m in IPO21/07/2021Download

An effective and accurate blood test should increase the screening detection rate and reduce mortality Lipidomic signature from plasma to detect localised breast cancer 

A/Prof. Gillian Lamoury, BMed FRANZCR, Radiation Oncologist

Prospectus

By downloading, printing or viewing the prospectus you acknowledge reading, and agree to the following terms:

Australia Prospectus

Disclaimer
The purpose of this webpage and subsequent document is to provide information to existing and prospective investors, and potential commercial partners, about the current status of BCAL’s research and development. It is not intended to promote the use or supply of any therapeutic goods.

Important Notice
You must read this important notice in its entirety before you attempt to access the electronic version of the Prospectus through this website. This notice does not form part of the Prospectus. You must read it before you attempt to access the electronic version of the Prospectus on this website and indicate your agreement or otherwise at the bottom of this notice.

The documents and other media on the following pages (Information) relate to an offer (Offer) of fully paid ordinary shares (Shares) in BCAL Diagnostics Limited (ACN 142 051 223) (Company).

The Offer is being made pursuant to a prospectus dated 4 June 2021 (Prospectus) which has been lodged with the Australian Securities and Investments Commission (ASIC). A copy of the Prospectus is available on this website. Neither ASIC nor ASX Limited take any responsibility for the contents of the Prospectus or for the merits of the investment to which it relates.

You should ensure that any copy of the Prospectus you view or print is completely downloaded. To the extent permitted by law, the Company is not liable for any loss incurred from accessing or downloading the Prospectus from this website, including, but not limited to, data corruption on download.

Selling Restrictions
The Prospectus does not constitute an offer or invitation in any place in which, or to any person to whom, it would not be lawful to make such an offer or invitation. No action has been taken to register or qualify the Shares the subject of the Prospectus, or the Offer, or otherwise to permit the public offering of the Shares, in any jurisdiction outside Australia. The Prospectus does not constitute an offer of Shares in any jurisdiction where, or to any person to whom, it would be unlawful to issue the Prospectus.

The distribution of the Prospectus (including an electronic copy) outside Australia may be restricted by law. If you come into possession of the Prospectus outside Australia, you should observe any such restrictions and should seek your own advice on those restrictions. Any failure to comply with such restrictions may contravene applicable securities laws.

The Information must not be released or distributed in the United States or to, or for the account or benefit of, any person in the United States, or in any jurisdiction outside of Australia where distribution may be restricted by law. The Information does not constitute an offer of Shares in the United States or to, or for the account or benefit of, any US person (as defined in Regulation S under the US Securities Act of 1933 (US Securities Act)), or to any person to whom it would not be lawful outside Australia and New Zealand. The Shares referred to in the Information have not been and will not be registered under the US Securities Act, as amended, or under the securities laws of any state or other jurisdiction of the United States. Any Shares described in, or sold pursuant to, the Information may not be offered or sold in the United States or to, or for the account or benefit of, any person in the United States absent registration under the US Securities Act or pursuant to an applicable exemption from, or a transaction not subject to, such registration, or to any person to whom it would not be lawful.

By proceeding you confirm that you have read, understood and agree to the full terms of this notice, and you represent, warrant and agree that:

1. you are a resident of Australia accessing this website from Australia;

2. you are a person who is eligible to receive the Prospectus and apply for Shares pursuant to the Offer; and

3. you are not in the United States nor are you a US person nor a person acting for the account or benefit of a US person.

Overseas Prospectus

Disclaimer
The purpose of this webpage and subsequent document is to provide information to existing and prospective investors, and potential commercial partners, about the current status of BCAL’s research and development. It is not intended to promote the use or supply of any therapeutic goods.

Important Notice
You must read this important notice in its entirety before you attempt to access the electronic version of the Prospectus through this website. This notice does not form part of the Prospectus. You must read it before you attempt to access the electronic version of the Prospectus on this website and indicate your agreement or otherwise at the bottom of this notice.

The documents and other media on the following pages (Information) relate to an offer (Offer) of fully paid ordinary shares (Shares) in BCAL Diagnostics Limited (ACN 142 051 223) (Company).

The Offer is being made pursuant to a prospectus dated 4 June 2021 (Prospectus) which has been lodged with the Australian Securities and Investments Commission (ASIC). A copy of the Prospectus is available on this website. Neither ASIC nor ASX Limited take any responsibility for the contents of the Prospectus or for the merits of the investment to which it relates.

You should ensure that any copy of the Prospectus you view or print is completely downloaded. To the extent permitted by law, the Company is not liable for any loss incurred from accessing or downloading the Prospectus from this website, including, but not limited to, data corruption on download.

Selling Restrictions
The Prospectus does not constitute an offer or invitation in any place in which, or to any person to whom, it would not be lawful to make such an offer or invitation. No action has been taken to register or qualify the Shares the subject of the Prospectus, or the Offer, or otherwise to permit the public offering of the Shares, in any jurisdiction outside Australia. The Prospectus does not constitute an offer of Shares in any jurisdiction where, or to any person to whom, it would be unlawful to issue the Prospectus.

The distribution of the Prospectus (including an electronic copy) outside Australia may be restricted by law. If you come into possession of the Prospectus outside Australia, you should observe any such restrictions and should seek your own advice on those restrictions. Any failure to comply with such restrictions may contravene applicable securities laws.

The Information must not be released or distributed in the United States or to, or for the account or benefit of, any person in the United States, or in any jurisdiction outside of Australia where distribution may be restricted by law. The Information does not constitute an offer of Shares in the United States or to, or for the account or benefit of, any US person (as defined in Regulation S under the US Securities Act of 1933 (US Securities Act)), or to any person to whom it would not be lawful outside Australia and New Zealand. The Shares referred to in the Information have not been and will not be registered under the US Securities Act, as amended, or under the securities laws of any state or other jurisdiction of the United States. Any Shares described in, or sold pursuant to, the Information may not be offered or sold in the United States or to, or for the account or benefit of, any person in the United States absent registration under the US Securities Act or pursuant to an applicable exemption from, or a transaction not subject to, such registration, or to any person to whom it would not be lawful.

By proceeding you confirm that you have read, understood and agree to the full terms of this notice, and you represent, warrant and agree that:

1. you are a resident of Australia accessing this website from Australia;

2. you are a person who is eligible to receive the Prospectus and apply for Shares pursuant to the Offer; and

3. you are not in the United States nor are you a US person nor a person acting for the account or benefit of a US person.

Register today and we will send you the prospectus soon.

Fill out the form below and we’ll be in touch.
Fill out the form below and we’ll be in touch.
*all fields are mandatory
Sign-Up To Receive The Latest Updates
2024 © BCAL Diagnostics
Privacy Policy
Terms & Conditions
Made by Eightball Media
crossmenu